DGAP-News: Eckert & Ziegler Strahlen- und Medizintechnik AG / Key word(s): Study30.11.2021 / 10:55 The issuer is solely responsible for the content of this announcement.Berlin / Toronto, 30 November 2021. Eckert & Ziegler Group is pleased to announce their partnership today with the Canadian Molecular Imaging Pr.
(1)
TORONTO, Jan. 12, 2021 (GLOBE NEWSWIRE) POINT Biopharma Inc. (POINT), a radiopharmaceutical company dedicated to bringing the many benefits of precision radioligand therapy to cancer patients, today announced that it has signed a licensing and commercialization agreement with CanProbe for exclusive rights to Lutetium - 177 Octreotate (Lu-DOTATATE) for the treatment of neuroendocrine cancer. CanProbe, a joint venture between the University Health Network (UHN) and the Centre for Probe Development and Commercialization (CPDC), developed Lu-DOTATATE as it is being used in 167 neuroendocrine tumor (NET) patients in a 180-patient trial with enrollment completed. CanProbe s NET clinical program has helped many patients in Ontario who previously had no other options for treatment, says Dr. Joe McCann, Chief Executive Officer of POINT Biopharma. We are excited to extend access to this treatment by leveraging CanProbe s intellectual property to seek regulatory approvals, with the
POINT Biopharma
POINT Biopharma Signs Exclusive License Agreement with CanProbe for the Commercialization of a Neuroendocrine Tumor Treatment
POINT Biopharma Signs Exclusive License Agreement with CanProbe for the Commercialization of a Neuroendocrine Tumor Treatment
TORONTO, Jan. 12, 2021 (GLOBE NEWSWIRE) POINT Biopharma Inc. (POINT), a radiopharmaceutical company dedicated to bringing the many benefits of precision radioligand therapy to cancer patients, today announced that it has signed a licensing and commercialization agreement with CanProbe for exclusive rights to Lutetium – 177 Octreotate (Lu-DOTATATE) for the treatment of neuroendocrine cancer. CanProbe, a joint venture between the University Health Network (UHN) and the Centre for Probe Development and Commercialization (CPDC), developed Lu-DOTATATE as it is being used in 167 neuroendocrine tumor (NET) patients in a 180-patient trial with enrollment completed.